


Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial: Erratum

In the article, “Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial”,^[1] which appeared in Volume 97, Issue 45 of *Medicine*, the disclosure statement should be “The authors report no other conflicts of interest.”

In Figure 5, the label for the first group should be HIV+ART+” instead of “HIV+ART–“.



In the caption for Figure 6, “D6=30 days post-dose 2” should be “D60=30 days post-dose 2”.

Reference

- [1] Kumarasamy N, Poongulali S, Beulah FE. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial. *Medicine*. 97;45:e13120.